X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/hep-b-biotech-antios-closed-after-fda-hold-proved-insurmountable
https://www.fiercebiotech.com/biotech/antios-therapy-could-be-bridge-hep-b-treatment-first-fda-hold-resolve
https://www.prnewswire.com/news-releases/antios-therapeutics-ati-2173-demonstrates-suppression-of-hepatitis-b-virus-in-phase-2a-study-ati-1428-and-ati-1645-exhibit-potent-antiviral-activity-in-a-nonclinical-study-301574996.html
https://www.prnewswire.com/news-releases/antios-therapeutics-announces-oral-presentations-on-ati-2173-ati-1428-and-ati-1645-hepatitis-b-virus-programs-at-the-easl-international-liver-congress-2022-301563419.html
https://www.trialsitenews.com/a/fda-places-clinical-hold-on-antios-hbv-therapy-ending-collaboration-with-assembly-af132372
https://medcitynews.com/2022/05/heart-trouble-report-clinical-hold-spell-end-of-antios-assembly-bio-hbv-alliance/
https://www.prnewswire.com/news-releases/antios-therapeutics-announces-notice-of-allowance-for-us-patent-on-phosphoramidates-for-the-treatment-of-hepatitis-b-virus-301532379.html
https://www.prnewswire.com/news-releases/antios-therapeutics-ati-2173-demonstrates-suppression-of-hepatitis-b-virus-in-phase-1b-and-2a-studies-301513247.html
https://www.globenewswire.com/news-release/2021/12/14/2351572/14025/en/Antios-Therapeutics-and-Arbutus-Biopharma-Announce-First-Patient-Dosed-in-Phase-2a-Combination-Trial-of-ATI-2173-AB-729-and-Tenofovir-Disoproxil-Fumarate-in-Patients-with-Chronic-H.html
https://www.biospace.com/article/releases/antios-therapeutics-announces-agreement-with-irbm-ingm-and-osr-to-acquire-fourth-generation-hbv-capsid-assembly-modulators-cams-/?s=71
Market Place
Share 
